Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration
Key takeaways
- Markets Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration By Russell Flannery,
- --:-- / --:--This voice experience is generated by AI.
- The two previously agreed in 2022 to collaborate on the development of a novel small-molecule therapeutic.
Markets Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration By Russell Flannery,
--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.David Ricks, chief executive officer of Eli Lilly & Co., speaks during the China Development Forum in Beijing in March this year. Photographer: Qilai Shen/Bloomberg© 2026 Bloomberg Finance LPIn the latest China pharmaceutical industry collaboration pact with a global drug leader, Abbisko said today it will work with U.S.-based Eli Lilly and Company to develop new drug candidates with global potential against disease targets selected by Lilly.
Abbisko, a cancer-focused biopharmaceutical company, will receive an upfront payment for an unstated amount and is eligible to receive up to $1.9 billion in development, regulatory and commercial milestone payments, along with royalties, the Shanghai-headquartered company said in a statement. The two previously agreed in 2022 to collaborate on the development of a novel small-molecule therapeutic.